AgeX Therapeutics Inc (AGE) has released an update to notify the public and investors about the unregistered sales of equity securities.
AgeX has significantly expanded its partnership with JuvVentures by automatically converting JuvVentures’ holdings of preferred stock into nearly 50 million shares of AgeX common stock. This strategic financial move, executed without the need for traditional registration due to an exemption in securities law, further intertwines the two companies and marks a notable shift in AgeX’s capital structure that could intrigue investors and market watchers alike.
For further insights into AGE stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
